Nov. 10, 2017—ArcherDx has signed an agreement to develop and commercialize a next-generation-sequencing–based oncology companion diagnostic for Celgene’s investigational drug CC-122 for indications in diffuse large B-Cell lymphoma.
Under the terms of the agreement, ArcherDx will use its patented Anchored Multiplex PCR technology combined with the Illumina MiSeqDx sequencing system and Archer Analysis bioinformatics software to develop the companion diagnostic. The assay is based on a proprietary gene expression signature developed by Celgene to identify DLBCL patients most likely to respond to CC-122, a cereblon-modulating agent currently under investigation in multiple disease settings. ArcherDx will retain the worldwide rights to commercialize the test and will pursue all filings with regional regulatory agencies.
“We look forward to this collaboration arrangement with Celgene to deliver on the promise of precision medicine in a disease indication with high unmet medical need,” Jason Myers, CEO of ArcherDx, said in a statement.